research 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
This study found no significant difference in the seroconversion rate of SARS-CoV2 IgG between patients with Immune Mediated Inflammatory diseases undergoing Targeted Immune-Modulating Therapies and those on conventional systemic treatment.